Waldencast Acquisition Corp., (NASDAQ: WALD) (“Waldencast”), a
special purpose acquisition company, today announced its
participation in the Cowen 6th Annual Future of the Consumer
Conference being held at the Westin Times Square in New York City,
New York.
Michel Brousset, Founder and Chief Executive Officer, will
participate in a fireside chat on Wednesday, May 25, 2022 at 2:45pm
ET. The Company’s management team will meet with investors during
the conference. The fireside chat will be available live and for
replay on the Investors Relations page on Waldencast’s website at
www.waldencast.com/investors-relations. Waldencast’s investor
presentation is also available on the Investors Relations page of
Waldencast’s website.
About Waldencast
Founded by Michel Brousset and Hind Sebti, Waldencast’s vision
is to build a global best-in-class beauty and wellness operating
platform by developing, acquiring, accelerating, and scaling the
next generation of conscious, purpose-driven brands.
Waldencast entered into agreements regarding its proposed business
combination with Obagi Global Holdings Limited (“Obagi”) and Milk
Makeup LLC (“Milk Makeup”) as a first step in realizing its vision.
Waldencast intends to seek brands with a direct connection to
today’s evolving consumers whose goals include pursuing social
responsibility, inclusiveness, sustainability, and transparency.
Its goal is to become the partner of choice for next-generation
brands and consumers by leveraging the collective leadership and
the industry-specific operating experience of its management
team.
IMPORTANT LEGAL INFORMATION
Additional Information and Where to Find It
This press release relates to proposed transactions between
Obagi and Waldencast and Milk Makeup and Waldencast. This press
release is not a proxy statement or solicitation of a proxy,
consent or authorization with respect to any securities or in
respect of the potential transactions and shall not constitute an
offer to sell or a solicitation of an offer to buy the securities
of Obagi or Milk Makeup, the combined company or Waldencast, nor
shall there be any sale of any such securities in any state or
jurisdiction in which such offer, solicitation, or sale would be
unlawful prior to registration or qualification under the
securities laws of such state or jurisdiction. In connection with
the proposed transactions, Waldencast filed a registration
statement on Form F-4 with the SEC on February 14, 2022, as amended
by Amendment No. 1 to the registration statement on Form F-4 filed
with the SEC on March 4, 2022, Amendment No. 2 to the registration
statement on Form F-4 filed with the SEC on March 18, 2022,
Amendment No. 3 to the registration statement on Form F-4 filed
with the SEC on April 27, 2022, and Amendment No. 4 to the
registration statement on Form F-4 filed with the SEC on May 13,
2022, which includes a document that serves as a prospectus and
proxy statement of Waldencast (the “proxy statement/prospectus”).
The proxy statement/prospectus will be sent to all Waldencast
shareholders. Waldencast also will file other documents regarding
the proposed transactions with the SEC. This communication does not
contain all the information that should be considered concerning
the proposed transactions and is not intended to form the basis of
any investment decision or any other decision in respect of the
proposed transactions. Before making any voting decision, investors
and security holders of Waldencast are urged to read the
registration statement, the proxy statement/prospectus and all
other relevant documents filed or that will be filed with the SEC
in connection with the proposed transactions as they become
available because they will contain important information about the
proposed transactions.
Investors and security holders may obtain free copies of the
registration statement, the proxy statement/prospectus and all
other relevant documents filed or that will be filed with the SEC
by Waldencast through the website maintained by the SEC
at www.sec.gov.
The documents filed by Waldencast with the SEC also may be
obtained free of charge at Waldencast’s website
at https://www.waldencast.com or upon written request to
10 Bank Street, Suite 560, White Plains, NY 10606.
Participants in the Solicitation
Waldencast, Obagi, and Milk Makeup, and their respective
directors and executive officers may be deemed to be participants
in the solicitation of proxies from Waldencast’s shareholders in
connection with the proposed transaction. A list of the names of
the directors and executive officers of Waldencast and information
regarding their interests in the business combinations is set forth
in Waldencast’s registration statement on Form S-1 (File No.
333-253370) filed with the SEC on March 15, 2021. Additional
information regarding the interests of such persons will be
contained in the registration statement and the proxy
statement/prospectus when available. You may obtain free copies of
these documents as described in the preceding paragraph.
Cautionary Statement Regarding Forward-Looking
Statements
This press release contains certain forward-looking statements
within the meaning of the federal securities laws with respect to
the proposed transactions among Obagi, Milk Makeup and Waldencast,
including statements regarding the intended benefits of the
transactions, the anticipated timing of the transactions and the
growth strategies of Waldencast, Obagi and Milk Makeup. These
forward-looking statements generally are identified by the words
“estimates,” “projects,” “expects,” “anticipates,” “forecasts,”
“plans,” “intends,” “believes,” “seeks,” “may,” “will,” “would,”
“should,” “future,” “propose,” “target,” “goal,” “objective,”
“outlook” and variations of these words or similar expressions (or
the negative versions of such words or expressions) are intended to
identify forward-looking statements. These forward-looking
statements are not guarantees of future performance, conditions or
results, and involve a number of known and unknown risks,
uncertainties, assumptions and other important factors, many of
which are outside the control of Waldencast, Obagi, and Milk
Makeup, that could cause actual results or outcomes to differ
materially from those discussed in the forward-looking statements.
Important factors, among others, that may affect actual results or
outcomes include, but are not limited to: (i) the risk that the
transactions may not be completed in a timely manner or at all,
which may adversely affect the price of Waldencast’s securities,
(ii) the risk that Waldencast shareholder approval of the proposed
transactions is not obtained, (iii) the inability to recognize the
anticipated benefits of the proposed transactions, which may be
affected by, among other things, the amount of funds available in
Waldencast’s trust account following any redemptions by
Waldencast’s shareholders, (iv) the failure to receive certain
governmental and regulatory approvals, (v) the inability to
complete the PIPE Investment or the Forward Purchase Agreements
investments (as such terms are defined in the registration
statement on Form F-4 discussed above), (vi) the occurrence of any
event, change or other circumstance that could give rise to the
termination of the Obagi Merger Agreement or the Milk Equity
Purchase Agreement (as such terms are defined in the registration
statement on Form F-4 discussed above), (vii) changes in general
economic conditions, including as a result of the COVID-19
pandemic, (viii) the outcome of litigation related to or arising
out of the proposed transactions, or any adverse developments
therein or delays or costs resulting therefrom, (ix) the effect of
the announcement or pendency of the transactions on Obagi’s or Milk
Makeup’s business relationships, operating results, and businesses
generally, (x) the ability to continue to meet Nasdaq’s listing
standards following the consummation of the proposed transactions,
(xi) costs related to the proposed transactions, (xii) that the
price of Waldencast’s securities may be volatile due to a variety
of factors, including Waldencast’s, Obagi’s or Milk Makeup’s
inability to implement their business plans or meet or exceed their
financial projections and changes in the combined capital
structure, (xiii) the ability to implement business plans,
forecasts, and other expectations after the completion of the
proposed transactions, and identify and realize additional
opportunities and (xiv) the ability of Obagi and Milk Makeup to
implement their strategic initiatives and continue to innovate
their existing products and anticipate and respond to market trends
and changes in consumer preferences. The foregoing list of factors
is not exhaustive. You should carefully consider the foregoing
factors and the other risks and uncertainties described in the
“Risk Factors” section of Waldencast’s registration statement on
Form S-1 (File No. 333-253370), the registration statement on Form
F-4 discussed above, the proxy statement/prospectus and other
documents filed or that may be filed by Waldencast from time to
time with the SEC. These filings identify and address other
important risks and uncertainties that could cause actual events
and results to differ materially from those contained in the
forward-looking statements. Forward-looking statements speak only
as of the date they are made. Readers are cautioned not to put
undue reliance on forward-looking statements, and Obagi, Milk
Makeup and Waldencast assume no obligation and do not intend to
update or revise these forward-looking statements, whether as a
result of new information, future events, or otherwise. Neither
Waldencast, Obagi, or Milk Makeup gives any assurance that
Waldencast, Obagi or Milk Makeup, or the combined company, will
achieve their expectations.
Contacts
InvestorsICR Allison
Malkininvestors@waldencast.com
MediaGladstone Place PartnersSteve
Lipin/Christina Stensonwaldencast@gladstoneplace.com
212-230-5930
Waldencast (NASDAQ:WALD)
Historical Stock Chart
From Aug 2024 to Sep 2024
Waldencast (NASDAQ:WALD)
Historical Stock Chart
From Sep 2023 to Sep 2024